P/B
—
Xeris Biopharma Holdings
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
Xeris Biopharma Holdings Inc is a biopharmaceutical company focused on developing and commercializing therapies for people with chronic endocrine and neurological diseases in the United States. It offer Recorlev for the treatment of Cushing’s syndrome, Gvoke for the treatment of severe hypoglycemia, and Keveyis for the treatment of Primary Periodic Paralysis (PPP).
$1.7B
Market Cap • 10/2/2026
2005
(21 years)
Founded
2018
(8 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
4,9
P/EBITDA
33,9
P/OCF
29,2
P/FCF
29,7
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
1,7B
EV
1,8B
EV/Revenue
5,4
EV/EBITDA
37,4
EV/EBIT
49,8
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,4%
Total Yield
-0,4%
Payout
0%
Retained Earnings
-700,2M
Profitability
Gross Margin
86,6%
EBITDA Margin
14,5%
EBIT Margin
10,9%
Net Margin
—
D&A/EBITDA
22,2%
R&D/Revenue
10,4%
Capex/Revenue
0,3%
Capex/D&A
7,7%
Capex/OCF
1,7%
SBC/OCF
49,7%
% PPE
6,5%
% Goodwill
5,5%
ROE
118,2%
ROIC
18,6%
Growth
CAGR Revenue 5Y
58,3%
CAGR Net Income 5Y
-27,2%
CAGR EPS 5Y
-39%
Leverage
N.D./EBITDA
3,4
Debt/Equity
0%
Current Ratio
1,4
Quick Ratio
0,9
Interest Coverage
129,5%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!